Site Variability in Cerebral Embolic Protection for Transcatheter Aortic Valve Implantation and Association With Outcomes

BackgroundThe effectiveness of CEPD in mitigating post-TAVI stroke remains uncertain, and therefore may be utilized differently across US hospitals. This study aims to characterize the hospital-level pattern cerebral embolic protection device (CEPD) use during transcatheter aortic valve implantation (TAVI) United States its association with outcomes.MethodsPatients treated nontransapical TAVI 2019 Nationwide Readmissions Database were included. Hospitals categorized as non-users users. The following outcomes compared: composite in-hospital or transient ischemic attack (TIA), stroke, death, cost hospitalization. Logistic regression models used for risk adjustment clinical outcomes.ResultsOf 41,822 encounters, was 10.6% (n = 4422). Out 392 hospitals, 65.8% non-user hospitals 34.2% No difference observed between users TIA (adjusted odds ratio (OR) 0.99 [0.86-1.15]), OR 1.00 [0.85-1.18]), death 0.86 [0.71-1.03]). hospitalization lower non-users.ConclusionsTwo-thirds do not TAVI, no significant neurologic among patients at user